Roche (OTCMKTS:RHHBY) Upgraded at Barclays

Barclays upgraded shares of Roche (OTCMKTS:RHHBY) from an equal weight rating to an overweight rating in a research note released on Tuesday, MarketBeat Ratings reports.

RHHBY has been the topic of several other reports. Zacks Research lowered Roche from a “hold” rating to a “strong sell” rating in a research report on Friday, December 5th. Hsbc Global Res upgraded Roche from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 2nd. Deutsche Bank Aktiengesellschaft raised Roche from a “sell” rating to a “hold” rating in a research report on Tuesday, November 11th. Morgan Stanley reaffirmed an “underweight” rating on shares of Roche in a research report on Tuesday, December 2nd. Finally, Jefferies Financial Group lowered shares of Roche from a “hold” rating to a “moderate sell” rating in a research note on Monday, October 27th. Three investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $57.00.

Roche Stock Performance

Roche stock opened at $52.77 on Tuesday. The firm has a fifty day moving average of $48.42 and a 200-day moving average of $43.78. Roche has a 52-week low of $34.75 and a 52-week high of $53.27. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.29 and a quick ratio of 1.02.

Hedge Funds Weigh In On Roche

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Rhumbline Advisers lifted its stake in Roche by 7.4% in the first quarter. Rhumbline Advisers now owns 107,252 shares of the company’s stock valued at $4,413,000 after buying an additional 7,374 shares during the last quarter. Confluence Investment Management LLC lifted its position in Roche by 5.1% in the 2nd quarter. Confluence Investment Management LLC now owns 15,225 shares of the company’s stock valued at $621,000 after purchasing an additional 734 shares during the last quarter. GAMMA Investing LLC lifted its position in Roche by 25.3% in the 2nd quarter. GAMMA Investing LLC now owns 16,101 shares of the company’s stock valued at $656,000 after purchasing an additional 3,251 shares during the last quarter. Boston Common Asset Management LLC grew its position in Roche by 11.1% in the 2nd quarter. Boston Common Asset Management LLC now owns 361,833 shares of the company’s stock worth $14,682,000 after purchasing an additional 36,101 shares during the last quarter. Finally, OLD National Bancorp IN increased its stake in shares of Roche by 2.9% in the second quarter. OLD National Bancorp IN now owns 261,317 shares of the company’s stock valued at $10,604,000 after purchasing an additional 7,326 shares during the period.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.